ProQR Therapeutics N.V

+0.08 (+1.98%)
Other Pre-Announcement

ProQR Announces Third Quarter 2020 Operating And Financial Results

Published: 11/16/2020 12:24 GMT
ProQR Therapeutics NV (PRQR) - Proqr Announces Third Quarter 2020 Operating and Financial Results.
Q3 Loss per Share EUR 0.26.
Q3 Earnings per Share Estimate EUR -0.34 -- Refinitiv Ibes Data (analyst estimates).
Qr-504a Clinical Study in Fuchs Expected to Start in H1 2021.
Initial Data From Phase 1/2 Trial of Qr-1123 Expected in 2021.
Enrollment Completed for Qr-421a Dosing Cohorts and Data From Next Phase 1/2 Interim Analysis Expected in H1 2021.
Illuminate Phase 2/3 Trial of Sepofarsen Expected to Complete Enrollment in Q1 2021.
Cash Runway Into 2023.